Clinical trial
Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus…
NCT00206219 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00206219 |
|---|---|
| Title | Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX) |
| Official title | A Phase III Randomised, Stratified, Parallel-Group, Multi-Centre, Comparative Study of ZD1839 (Iressa®) 250 Mg and 500 Mg Versus Methotrexate for Previously Treated Patients With Squamous Cell Carcinoma of the Head and Neck |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Squamous Cell Carcinoma of the Head and Neck |
| Intervention type | Drug |
| Interventions | Gefitinib, methotrexate |
| Enrollment | 477 |
| Start date | Nov 1, 2003 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Sep 21, 2005 |
| Last update posted | Jan 27, 2011 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Croatia, Czechia, Estonia, Greece, India, Israel, Italy and 13 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: